|
Dr. Nurbhai is vice president for clinical development at Dynogen. Prior to joining Dynogen, he was executive director and head of CNS clinical research and development at Pfizer, Inc. in Groton/New London Connecticut. Prior to that, he was global clinical team leader on the overactive bladder development team and site therapeutic area leader for GI and GU development with responsibility for GI development programs and clinical input for GI licensing opportunities. He joined Pfizer in Sandwich, England in 1993, initially working as a clinician on multinational late Phase II Programs in both irritable bowel syndrome and urinary urge incontinence. He subsequently held positions of increasing responsibility across a number of therapeutic areas and throughout his career has been a major contributor to the development, regulatory submission and approval of compounds in the anti-bacterial, sexual dysfunction, antifungal, and GI/GU therapeutic areas. Prior to joining Pfizer, Dr. Nurbhai practiced medicine in the gastroenterology department of Broad Green Hospital in Liverpool, England.Dr. Nurbhai qualified in Medicine at Dundee University in Scotland. He completed his postgraduate general medical training at the University of Manchester during which time he was elected to the Membership of the Royal College of Physicians of the United Kingdom. | 